Solara Active Pharma Sciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Poorvank Purohit

Chief executive officer

₹5.0m

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	1.5yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

CEO

Poorvank Purohit (44 yo)

1.3yrs

Tenure

₹5,000,000

Compensation

Mr. Poorvank Purohit serves as Chief Executive Officer of Solara Active Pharma Sciences Limited since February 03, 2023 and serves as its Director & Managing Director since July 2023. He started his career...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Poorvank Purohit	MD, CEO & Director	1.3yrs	₹5.00m	no data
Mohan Muthunarayanan	COO & Executive Director	1.8yrs	no data	no data
Suddapalli Krishna	Company Secretary	6.2yrs	₹4.20m	no data
Arun Pillai	Founder & Non-Executive Director	no data	no data	7.62% ₹ 1.5b
Arun Baskaran	Chief Financial Officer	less than a year	no data	no data
Hero Velladurai	Chief Scientific Officer	no data	no data	no data
V. Moorthy	Chief Quality Officer	no data	no data	no data

1.5yrs

Average Tenure

Experienced Management: 541540's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Poorvank Purohit	MD, CEO & Director	less than a year	₹5.00m	no data
Mohan Muthunarayanan	COO & Executive Director	less than a year	no data	no data
Arun Pillai	Founder & Non-Executive Director	2.8yrs	no data	7.62% ₹ 1.5b
Ankur Thadani	Non-Executive Director	5yrs	no data	no data
Kausalya Santhanam	Independent Director	6.1yrs	₹800.00k	no data
Ramakrishnan Rajagopal	Independent Director	6.1yrs	₹800.00k	no data
Rajendra Srivastava	Independent Director	less than a year	no data	no data
Kartheek Raju	Non-Executive Non-Independent Director	2.8yrs	no data	no data
Rajiv Nabar	Independent Director	less than a year	no data	no data

2.8yrs

Average Tenure

56yo

Average Age

Experienced Board: 541540's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Solara Active Pharma Sciences Management

Management criteria checks 1/4

Key information

Recent management updates

Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial Officer

High number of new directors

Solara Active Pharma Sciences Limited Appoints P V Raghavendra Rao as Chief Financial Officer

Independent Director recently sold ₹183k worth of stock

Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 15, 2023

Solara Active Pharma Sciences Limited Announces Resignation of Directors

Recent updates

Now 21% overvalued after recent price rise

Now 20% overvalued after recent price rise

An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited (NSEI:SOLARA).

Third quarter 2024 earnings released: ₹76.49 loss per share (vs ₹0.12 profit in 3Q 2023)

Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial Officer

Solara Active Pharma Sciences Limited to Report Q3, 2024 Results on Feb 14, 2024

High number of new directors

Second quarter 2024 earnings released: ₹4.77 loss per share (vs ₹2.77 loss in 2Q 2023)

Solara Active Pharma Sciences Limited Appoints P V Raghavendra Rao as Chief Financial Officer

Price target decreased by 9.0% to ₹407

Independent Director recently sold ₹183k worth of stock

Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 15, 2023

Now 20% undervalued

First quarter 2024 earnings released: ₹5.43 loss per share (vs ₹4.56 loss in 1Q 2023)

Solara Active Pharma Sciences Limited Announces Resignation of Directors

High number of new directors

Solara Active Pharma Sciences Limited Announces Executive Changes

Solara Active Pharma Sciences Limited Announces Resignation of S Hariharan as Executive Director

Solara Active Pharma Sciences Limited Announces Resignation of Jitesh Devendra as A Managing Director and Director

MD & Director recently sold ₹5.5m worth of stock

Independent Director recently sold ₹7.3m worth of stock

Insider recently sold ₹3.6m worth of stock

Insider recently sold ₹1.8m worth of stock

Price target decreased by 8.9% to ₹447

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Solara Active Pharma Sciences Limited to Report Q4, 2023 Results on May 12, 2023

Price target decreased by 8.1% to ₹491

USFDA concludes inspection at Solara's Visakhapatnam (Vizag) facility with Zero 483 inspectional observations

Third quarter 2023 earnings released: EPS: ₹0.12 (vs ₹38.93 loss in 3Q 2022)

Solara Active Pharma Sciences Limited Appoints Poorvank Purohit as Chief Executive Officer, Effective from 3 February, 2023

Solara Active Pharma Sciences Limited to Report Q3, 2023 Results on Jan 25, 2023

High number of new directors

Second quarter 2023 earnings released: ₹2.77 loss per share (vs ₹8.27 profit in 2Q 2022)

Solara Active Pharma Sciences Limited to Report Q2, 2023 Results on Nov 09, 2022

Solara Active Pharma Sciences Limited Receives European Approval to Manufacture Ibuprofen from Its Vizag Facility

Now 21% undervalued

Now 20% undervalued

Now 21% undervalued

Insider recently bought ₹390k worth of stock

Insider recently bought ₹1.3m worth of stock

Now 20% undervalued

Solara Active Pharma Sciences Limited Announces Resignation of Mr. Kartheek Raju as Director

Full year 2022 earnings: EPS and revenues miss analyst expectations

Solara Active Pharma Sciences Limited to Report Q1, 2023 Results on Aug 04, 2022

Solara Active Pharma Sciences Limited, Annual General Meeting, Aug 25, 2022

Price target decreased to ₹811

Insider recently bought ₹413k worth of stock

Price target decreased to ₹934

Solara Active Pharma Sciences Limited Announces Resignation of Mr. Rajender Juwadi Rao as Managing Director and Director

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 23% undervalued after recent price drop

Solara Active Pharma Sciences Limited to Report Q4, 2022 Results on Apr 29, 2022

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

Solara Active Pharma Sciences Limited Announces Executive Changes

Now 32% undervalued after recent price drop

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Solara Active Pharma Sciences Limited Announces Executive Changes

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Price target decreased to ₹1,551

CFO & Executive Director recently sold ₹525k worth of stock

CFO & Executive Director recently sold ₹1.2m worth of stock

Insider recently bought ₹10m worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS ₹8.27 (vs ₹19.21 in 2Q 2021)

Price target decreased to ₹1,842

Insider recently sold ₹6.8m worth of stock

Insider recently bought ₹26m worth of stock